Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Simge Acar, Amy E. Armstrong & Angela C. Hirbe. (2022) Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. Expert Opinion on Investigational Drugs 31:1, pages 31-40.
Read now
Read now
Xiaoqin Yang, Kaushal Desai, Neha Agrawal, Kirti Mirchandani, Sagnik Chatterjee, Eric Sarpong & Shuvayu Sen. (2021) Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a medicaid population. Current Medical Research and Opinion 37:9, pages 1555-1561.
Read now
Read now
Sabyasachi Mukhopadhyay, Arpita Maitra & Shouvik Choudhury. (2021) Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. Current Medical Research and Opinion 37:5, pages 789-794.
Read now
Read now
Xiaoqin Yang, Kaushal Desai, Neha Agrawal, Kirti Mirchandani, Sagnik Chatterjee, Eric Sarpong & Shuvayu Sen. (2020) Treatment, Resource Use and Costs Among Pediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas. Pediatric Health, Medicine and Therapeutics 11, pages 421-428.
Read now
Read now
James A. Walker & Meena Upadhyaya. (2018) Emerging therapeutic targets for neurofibromatosis type 1. Expert Opinion on Therapeutic Targets 22:5, pages 419-437.
Read now
Read now
Diana Bradford, Karlyne M Reilly, Brigitte C Widemann, Abby Sandler & Shivaani Kummar. (2016) Developing therapies for rare tumors: opportunities, challenges and progress. Expert Opinion on Orphan Drugs 4:1, pages 93-103.
Read now
Read now
Nicole M Brossier & David H Gutmann. (2015) Improving outcomes for neurofibromatosis 1–associated brain tumors. Expert Review of Anticancer Therapy 15:4, pages 415-423.
Read now
Read now
Articles from other publishers (61)
Kim M. Keeling, Andre Leier, David M. Bedwell, Ann T. Chen, Robert A. Kesterson, Tatiana T. Marquez Lago, Ulrich F. Müller, Jiangbing Zhou, Linda Popplewell & Deeann Wallis. 2024. Comprehensive Precision Medicine. Comprehensive Precision Medicine
249
271
.
Prabhumallikarjun Patil, Bojana Borislavova Pencheva, Vinayak Mahesh Patil & Jason Fangusaro. (2022) Nervous system (NS) Tumors in Cancer Predisposition Syndromes. Neurotherapeutics 19:6, pages 1752-1771.
Crossref
Crossref
Xiaoqin Yang, Hyun Kyoo Yoo, Suvina Amin, Wendy Y. Cheng, Sanjana Sundaresan, Lujia Zhang & Mei Sheng Duh. (2022) Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA. Child's Nervous System 38:8, pages 1513-1522.
Crossref
Crossref
Nada Alnefaie, Othman T. Almutairi, Abdulrahman Y. Alturki & Mohammed Bafaquh. (2022) Bibliometric analysis of the top 100 most-cited articles in neurofibromatosis. Surgical Neurology International 13, pages 282.
Crossref
Crossref
Chih-Kai Hsu, Rafael Denadai, Chun-Shin Chang, Chuan-Fong Yao, Ying-An Chen, Pang-Yun Chou, Lun-Jou Lo & Yu-Ray Chen. (2022) The Number of Surgical Interventions and Specialists Involved in the Management of Patients with Neurofibromatosis Type I: A 25-Year Analysis. Journal of Personalized Medicine 12:4, pages 558.
Crossref
Crossref
Milena Jankovic, Bojana Petrovic, Ivana Novakovic, Slavko Brankovic, Natasa Radosavljevic & Dejan Nikolic. (2022) The Genetic Basis of Strokes in Pediatric Populations and Insight into New Therapeutic Options. International Journal of Molecular Sciences 23:3, pages 1601.
Crossref
Crossref
Lauren D. Sanchez, Ashley Bui & Laura J. Klesse. (2021) Targeted Therapies for the Neurofibromatoses. Cancers 13:23, pages 6032.
Crossref
Crossref
I. Solares, D. Viñal, M. Morales-Conejo, N. Rodriguez-Salas & J. Feliu. (2021) Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review. ESMO Open 6:4, pages 100223.
Crossref
Crossref
Verena Gerlinde Frings & Matthias Goebeler. (2021) Klinische Dermatologie: Die Pipelines sind gefüllt. Deutsches Ärzteblatt Online.
Crossref
Crossref
Robert Galvin, Adrienne L. Watson, David A. Largaespada, Nancy Ratner, Sara Osum & Christopher L. Moertel. (2021) Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib. Current Oncology Reports 23:4.
Crossref
Crossref
Christina Bergqvist & Pierre Wolkenstein. (2021) MEK inhibitors in RASopathies. Current Opinion in Oncology 33:2, pages 110-119.
Crossref
Crossref
Michael J. Fisher, Chie-Schin Shih, Steven D. Rhodes, Amy E. Armstrong, Pamela L. Wolters, Eva Dombi, Chi Zhang, Steven P. Angus, Gary L. Johnson, Roger J. Packer, Jeffrey C. Allen, Nicole J. Ullrich, Stewart Goldman, David H. Gutmann, Scott R. Plotkin, Tena Rosser, Kent A. Robertson, Brigitte C. Widemann, Abbi E. Smith, Waylan K. Bessler, Yongzheng He, Su-Jung Park, Julie A. Mund, Li Jiang, Khadijeh Bijangi-Vishehsaraei, Coretta Thomas Robinson, Gary R. Cutter, Bruce R. Korf, Chie-Schin Shih, Amy E. Armstrong, Jaishri O. Blakeley & D. Wade Clapp. (2021) Cabozantinib for neurofibromatosis type 1–related plexiform neurofibromas: a phase 2 trial. Nature Medicine 27:1, pages 165-173.
Crossref
Crossref
Christina Bergqvist, Amandine Servy, Laurence Valeyrie-Allanore, Salah Ferkal, Patrick Combemale & Pierre Wolkenstein. (2020) Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Srivandana Akshintala, Andrea Baldwin, David J Liewehr, Anne Goodwin, Jaishri O Blakeley, Andrea M Gross, Seth M Steinberg, Eva Dombi & Brigitte C Widemann. (2020) Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro-Oncology 22:9, pages 1368-1378.
Crossref
Crossref
Olga Nigro, Andrea Coppola, Tiziana Tartaro, Alessandro Tuzi, Ilaria Vallini & Graziella Pinotti. (2020) Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature. Anti-Cancer Drugs 31:7, pages 754-757.
Crossref
Crossref
Amy E. Armstrong, Steven D. Rhodes, Abbi Smith, Shi Chen, Waylan Bessler, Michael J. Ferguson, Li Jiang, Xiaohong Li, Jin Yuan, Xianlin Yang, Feng‐Chun Yang, Kent A. Robertson, David A. Ingram, Jaishri O. Blakeley & D. Wade Clapp. (2020) Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1. Pediatric Blood & Cancer 67:8.
Crossref
Crossref
Julie A. Mund, SuJung Park, Abbi E. Smith, Yongzheng He, Li Jiang, Eric Hawley, Michelle J. Roberson, Dana K. Mitchell, Mohannad Abu-Sultanah, Jin Yuan, Waylan K. Bessler, George Sandusky, Shi Chen, Chi Zhang, Steven D. Rhodes & D. Wade Clapp. (2020) Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 17. Journal of Biological Chemistry 295:29, pages 9948-9958.
Crossref
Crossref
Amy E Armstrong, Nicole M Brossier & Angela C Hirbe. (2020) Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape. The Lancet Child & Adolescent Health 4:7, pages 488-490.
Crossref
Crossref
Andre Leier, David M. Bedwell, Ann T. Chen, George Dickson, Kim M. Keeling, Robert A. Kesterson, Bruce R. Korf, Tatiana T. Marquez Lago, Ulrich F. Müller, Linda Popplewell, Jiangbing Zhou & Deeann Wallis. (2020) Mutation-Directed Therapeutics for Neurofibromatosis Type I. Molecular Therapy - Nucleic Acids 20, pages 739-753.
Crossref
Crossref
Crystal D.C. Kamilaris, Fady Hannah-Shmouni & Constantine A. Stratakis. (2020) Adrenocortical tumorigenesis: Lessons from genetics. Best Practice & Research Clinical Endocrinology & Metabolism 34:3, pages 101428.
Crossref
Crossref
Andrea M. GrossPamela L. WoltersEva DombiAndrea BaldwinPatricia WhitcombMichael J. FisherBrian WeissAeRang KimMiriam BornhorstAmish C. ShahStaci MartinMarie C. RoderickDominique C. PichardAmanda CarbonellScott M. PaulJanet TherrienOxana KapustinaKara HeiseyD. Wade ClappChi ZhangCody J. PeerWilliam D. Figg, Malcolm SmithJohn GlodJaishri O. BlakeleySeth M. SteinbergDavid J. VenzonL. Austin DoyleBrigitte C. Widemann. (2020) Selumetinib in Children with Inoperable Plexiform Neurofibromas. New England Journal of Medicine 382:15, pages 1430-1442.
Crossref
Crossref
Bruce R. Korf. 2020. Multidisciplinary Approach to Neurofibromatosis Type 1. Multidisciplinary Approach to Neurofibromatosis Type 1
261
272
.
Andrea M. Gross, Eva Dombi & Brigitte C. Widemann. 2020. Multidisciplinary Approach to Neurofibromatosis Type 1. Multidisciplinary Approach to Neurofibromatosis Type 1
165
179
.
Sergey Gorelyshev, Endzhe Valiakhmetova & Igor Pronin. 2020. Textbook of Pediatric Neurosurgery. Textbook of Pediatric Neurosurgery
965
988
.
Faliang Gao, Min Li, Zheng Wang, Lingfei Shi, Lin Lou & Jia Zhou. (2019) Efficacy and Safety of Gamma Knife Radiosurgery for Meningiomas in Patients with Neurofibromatosis Type 2: A Long-Term Follow-Up Single-Center Study. World Neurosurgery 125, pages e929-e936.
Crossref
Crossref
Olga Nigro, Tiziana Tartaro, Alessandro Tuzi, Alice Giaquinto, Matteo B. Suter & Graziella Pinotti. (2019) Long-term therapy with bevacizumab in a young patient affected by NF-2. Anti-Cancer Drugs 30:3, pages 318-321.
Crossref
Crossref
Ashley Cannon, Mei-Jan Chen, Peng Li, Kevin P. Boyd, Amy Theos, David T. Redden & Bruce Korf. (2018) Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study. Orphanet Journal of Rare Diseases 13:1.
Crossref
Crossref
Andrea M Gross, Gurbani Singh, Srivandana Akshintala, Andrea Baldwin, Eva Dombi, Somto Ukwuani, Anne Goodwin, David J Liewehr, Seth M Steinberg & Brigitte C Widemann. (2018) Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Neuro-Oncology 20:12, pages 1643-1651.
Crossref
Crossref
Douglas R Stewart, Bruce R Korf, Katherine L Nathanson, David A Stevenson & Kaleb Yohay. (2018) Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine 20:7, pages 671-682.
Crossref
Crossref
Michael Kinori, Nickisa Hodgson & Janice Lasky Zeid. (2018) Ophthalmic manifestations in neurofibromatosis type 1. Survey of Ophthalmology 63:4, pages 518-533.
Crossref
Crossref
A. Casal, N. Rodríguez-Núñez, A. Martínez-Alegría, S. Candamio, J. Álvarez & L. Valdés. (2018) Neurofibromatosis type I with lung involvement in a cancer patient. Pulmonology 24:4, pages 269-271.
Crossref
Crossref
Marc Ferrer, Sara J. C. Gosline, Marigo Stathis, Xiaohu Zhang, Xindi Guo, Rajarshi Guha, Dannielle A. Ryman, Margaret R. Wallace, Laura Kasch-Semenza, Haiping Hao, Roxann Ingersoll, David Mohr, Craig Thomas, Sharad Verma, Justin Guinney & Jaishri O. Blakeley. (2018) Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Scientific Data 5:1.
Crossref
Crossref
Michael J. Fisher, Allan J. Belzberg, Peter de Blank, Thomas De Raedt, Florent Elefteriou, Rosalie E. Ferner, Marco Giovannini, Gordon J. Harris, Michel Kalamarides, Matthias A. Karajannis, AeRang Kim, Conxi Lázaro, Lu Q. Le, Wei Li, Robert Listernick, Staci Martin, Helen Morrison, Eric Pasmant, Nancy Ratner, Elisabeth Schorry, Nicole J. Ullrich, David Viskochil, Brian Weiss, Brigitte C. Widemann, Yuan Zhu, Annette Bakker & Eduard Serra. (2018) 2016 Children's Tumor Foundation conference on neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis. American Journal of Medical Genetics Part A 176:5, pages 1258-1269.
Crossref
Crossref
Cynthia J. Campen & David H. Gutmann. (2017) Optic Pathway Gliomas in Neurofibromatosis Type 1. Journal of Child Neurology 33:1, pages 73-81.
Crossref
Crossref
Roger J. Packer, Michael J. Fisher, Gary Cutter, Karen Cole-Plourde & Bruce R. Korf. (2017) Neurofibromatosis Clinical Trial Consortium. Journal of Child Neurology 33:1, pages 82-91.
Crossref
Crossref
Patrick J. Cimino & David H. Gutmann. 2018. Neurogenetics, Part II. Neurogenetics, Part II
799
811
.
Jian CampianDavid H. Gutmann. (2017) CNS Tumors in Neurofibromatosis. Journal of Clinical Oncology 35:21, pages 2378-2385.
Crossref
Crossref
Annette C. Bakker, Salvatore La Rosa, Larry S. Sherman, Pamela Knight, Hyerim Lee, Patrice Pancza & Marco Nievo. (2017) Neurofibromatosis as a gateway to better treatment for a variety of malignancies. Progress in Neurobiology 152, pages 149-165.
Crossref
Crossref
David H. Gutmann, Rosalie E. Ferner, Robert H. Listernick, Bruce R. Korf, Pamela L. Wolters & Kimberly J. Johnson. (2017) Neurofibromatosis type 1. Nature Reviews Disease Primers 3:1.
Crossref
Crossref
Souvik Karmakar & Karlyne M Reilly. (2017) The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncology 6:1, pages 45-60.
Crossref
Crossref
AeRang Kim, Douglas R. Stewart, Karlyne M. Reilly, David Viskochil, Markku M. Miettinen & Brigitte C. Widemann. (2017) Malignant Peripheral Nerve Sheath Tumors State of the Science: Leveraging Clinical and Biological Insights into Effective Therapies. Sarcoma 2017, pages 1-10.
Crossref
Crossref
Robert A. Avery, James A. Katowitz, Michael J. Fisher, Gena Heidary, Eva Dombi, Roger J. Packer, Brigitte C. Widemann, Kelly A. Hutcheson, William P. Madigan, Robert Listernick, Grant T. Liu, Jerry E. Berland, Edmond J. FitzGibbon & Bruce R. Korf. (2017) Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1. Ophthalmology 124:1, pages 123-132.
Crossref
Crossref
A. Theos & B.R. Korf. 2017. Reference Module in Neuroscience and Biobehavioral Psychology. Reference Module in Neuroscience and Biobehavioral Psychology.
Sergey Gorelyshev, Endzhe Valiakhmetova & Igor Pronin. 2017. Textbook of Pediatric Neurosurgery. Textbook of Pediatric Neurosurgery
1
32
.
Daniel Coluccia, Adrienne Weeks, Javier Fandino, Christian Schneider, Christian Smith & James T. Rutka. 2017. The Molecular Basis of Human Cancer. The Molecular Basis of Human Cancer
657
694
.
Eva Dombi, Andrea Baldwin, Leigh J. Marcus, Michael J. Fisher, Brian Weiss, AeRang Kim, Patricia Whitcomb, Staci Martin, Lindsey E. Aschbacher-Smith, Tilat A. Rizvi, Jianqiang Wu, Rachel Ershler, Pamela Wolters, Janet Therrien, John Glod, Jean B. Belasco, Elizabeth Schorry, Alessandra Brofferio, Amy J. Starosta, Andrea Gillespie, Austin L. Doyle, Nancy Ratner & Brigitte C. Widemann. (2016) Activity of Selumetinib in Neurofibromatosis Type 1?Related Plexiform Neurofibromas. New England Journal of Medicine 375:26, pages 2550-2560.
Crossref
Crossref
Bo Gyung Kim, Takeshi Fujita, Konstantina M. Stankovic, D. Bradley Welling, In Seok Moon, Jae Young Choi, Jieun Yun, Jong Soon Kang & Jong Dae Lee. (2016) Sulforaphane, a natural component of broccoli, inhibits vestibular schwannoma growth in vitro and in vivo. Scientific Reports 6:1.
Crossref
Crossref
Chung-Ping Liao, Sanjay Pradhan, Zhiguo Chen, Amish J. Patel, Reid C. Booker & Lu Q. Le. (2016) The role of nerve microenvironment for neurofibroma development. Oncotarget 7:38, pages 61500-61508.
Crossref
Crossref
Brigitte C. WidemannScott R. Plotkin. (2016) Consensus for NF clinical trials. Neurology 87:7_Supplement_1.
Crossref
Crossref
Jaishri O. Blakeley & Scott R. Plotkin. (2016) Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro-Oncology 18:5, pages 624-638.
Crossref
Crossref
Bruce R. Korf. 2016. Health Care for People with Intellectual and Developmental Disabilities across the Lifespan. Health Care for People with Intellectual and Developmental Disabilities across the Lifespan
833
845
.
Martino Ruggieri, Andrea Domenico Pratic?Dafydd Gareth Evans. (2015) Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms. Seminars in Pediatric Neurology 22:4, pages 240-258.
Crossref
Crossref
Nancy Ratner & Shyra J. Miller. (2015) A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nature Reviews Cancer 15:5, pages 290-301.
Crossref
Crossref
Matthias A. Karajannis & Rosalie E. Ferner. (2015) Neurofibromatosis-related tumors. Current Opinion in Pediatrics 27:1, pages 26-33.
Crossref
Crossref
Jacqueline L. Anderson & David H. Gutmann. 2015. Neurocutaneous Syndromes. Neurocutaneous Syndromes
75
86
.
Jeremie Vitte & Marco Giovannini. 2015. Heat Shock Protein-Based Therapies. Heat Shock Protein-Based Therapies
257
271
.
Brigitte C. Widemann, Dusica Babovic-Vuksanovic, Eva Dombi, Pamela L. Wolters, Stewart Goldman, Staci Martin, Anne Goodwin, Wendy Goodspeed, Mark W. Kieran, Bruce Cohen, Susan M. Blaney, Allison King, Jeffrey Solomon, Nicholas Patronas, Frank M. Balis, Elizabeth Fox, Seth M. Steinberg & Roger J Packer. (2014) Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatric Blood & Cancer 61:9, pages 1598-1602.
Crossref
Crossref
Stephanie Hui-Su Lim, Simone Ardern-Holmes, Geoffrey McCowage & Paul de Souza. (2014) Systemic therapy in neurofibromatosis type 2. Cancer Treatment Reviews 40:7, pages 857-861.
Crossref
Crossref
Angela C Hirbe & David H Gutmann. (2014) Neurofibromatosis type 1: a multidisciplinary approach to care. The Lancet Neurology 13:8, pages 834-843.
Crossref
Crossref
David H. Gutmann. (2014) Eliminating barriers to personalized medicine. Neurology 83:5, pages 463-471.
Crossref
Crossref
Andrew L. Lin & David H. Gutmann. (2013) Advances in the treatment of neurofibromatosis-associated tumours. Nature Reviews Clinical Oncology 10:11, pages 616-624.
Crossref
Crossref